#Santé & Bien-être #Therapeutics
- Big data
- Artificial intelligence
- Network pharmacology
- Drug repurposing
- Molecule combinations
As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.Discover >
Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.Discover >
Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.Discover >
Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.Discover >
#Santé & Bien-être #Therapeutics
Pharnext develops new therapies and biomarkers based on network pharmacology with a proprietary discovery platform. The company is focused on pathologies with high unmet medical needs. These include neurodegenerative, orphan and common diseases (Charcot-Marie-Tooth disease Type 1A, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS)).
Pharnext was founded by renowned scientists and entrepreneurs (including Professor Daniel Cohen, a pioneer in modern genomics) to develop new therapies targeting several key pathological mechanisms in severe orphan and common neurodegenerative diseases.
DESCRIPTION OF THE PRODUCTS / SERVICES / TECHNOLOGY
Pharnext’s approach is applicable to virtually any disorder and particularly suited to multifactorial diseases.
Pharnext is currently focused on neurodegenerative diseases:
CUSTOMER REFERENCES / COLLABORATIONS / HIGHLIGHTS
€91 million in equity raised from a foundation.
60 patent families
45 staff members
New paradigm in R&D for faster pharmaceutical developments, particularly in multifactorial diseases. Eminent scientists and breakthrough approaches in pharmacogenomics.
Innovative drug combinations based on genomic big data and artificial intelligence. Pharnext’s approach can potentially be applied to any disease.
In same field
– Characterization of antigen / antibody interactions (epitope / paratope) – Optimization of therapeutic antibodiesDiscover
Phagos is developing the use of bacteriophages, a bacterial virus, for controlling infectious diseases in aquaculture.Discover
Biotechnology, R&D, Drug development, oncology, obesity, infectious diseasesDiscover
Synsight is a company specializing in the discovery and preclinical development of new therapeutic molecules, based on a proprietary, integrated platform, combining artificial intelligence, molecular modeling and a functional experimental screening approach of High-Content Screening (HCS ).Discover
Santen SAS has developed its own sales force to commercialize ophthalmic products in France while Novagali Innovation Center is a center of excellence for Santen Group dedicated to research and development of innovative ophthalmic treatments for all segments of the eye.Discover
R & D services in the field of transient expression of recombinant proteins in plants.Discover
Pharming specializes in the production of recombinant proteins in transgenic rabbit milk.Discover
PEP-Therapy develops innovative peptides as targeted therapies in oncology. The company operates a unique therapeutic technology based on cell penetrating & interfering peptides (CP&IP). These innovative molecules penetrate cells and specifically block relevant intracellular protein-protein interactions, thus inhibiting key pathological mechanisms.Discover
GenoSafe is a full contract research and consulting organization specialized in evaluating the quality, safety and efficacy of innovative biological products. Our goal is to enable our clients to move their products along clinical development rapidly and efficiently.Discover
Discovery, development and production of innovative therapies for rare genetic diseases, notably neuromuscular diseases.Discover
By means of its autonomous messenger RNA synthesis platform, Eukarÿs develops 1) systems for the bioproduction of viruses and recombinant proteins and 2) preventative vaccines for viral infectious diseases and treatments in immuno-oncology.Discover
Enterome develops and commercializes therapies for disorders associated with disruption of the intestinal microbiota.Discover
Research, development and commercialization of tyrosine kinase inhibitors as targeted therapy for pathologies with unmet medical needs.Discover